8-K Announcements
6Material company update
Dec 30, 2025·SEC
Material company update
Dec 12, 2025·SEC
Material company update
Dec 9, 2025·SEC
Merus N.V. operates as a high-risk, clinical-stage biotechnology firm whose valuation is tethered to the success of its Biclonics and Triclonics platforms rather than consistent commercial revenue. While the company maintains a substantial liquidity buffer, th...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue remains highly volatile due to milestone-driven accounting, with quarterly figures fluctuating between $6.8M and $24.5M while R&D expenses reached a peak of $79.7M in 2025Q2.
Genmab's acquisition of Merus for $97 per share was well received by the market, reflecting confidence in the deal despite its size, with a 2.2% absolute or 11.1% annualized spread.
Merus is collaborating with Biohaven on three programs, combining Merus' bispecific antibody candidates with Biohaven's linker and payload technologies, indicating growth potential.
The market reacted positively to Merus' acquisition by Genmab, with Genmab's stock also performing well, signaling strong investor confidence in the transaction.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2025Latest Oct 31, 2025 | -$1.23+0.0% vs -$1.23 | $12M+41.4% vs $9M |
Q3 2025 Aug 5, 2025 | -$2.23-90.6% vs -$1.17 | $9M-14.7% vs $10M |
Q2 2025 May 7, 2025 | -$1.40-28.2% vs -$1.09 | $26M+243.0% vs $8M |
Q1 2025 Feb 27, 2025 | -$0.41+53.9% vs -$0.89 | $9M-14.8% vs $11M |
Benchmark MRUS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Merus N.V. (MRUS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $90.00 | $6.83B | -26.87 | -12.38% | -595.93% | -41.39% | — | |
| $27.57 | $2.03B | -25.52 | 38.87% | -138685.11% | -222.5% | — | |
| $37.29 | $7.7B | -13.46 | — | -7585.86% | -69.59% | — | |
| $8.70 | $362.29M | -2558.82 | 10.37% | 69.76% | — | — | |
| $2.58 | $300.72M | -2.24 | -51.24% | -1941.09% | -65.08% | — | |
| $25.16 | $1.87B | -20.29 | 13.65% | -155.59% | -28.66% | — |
Merus N.V. (MRUS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Merus N.V. (MRUS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Dec 30, 2025·SEC
Dec 12, 2025·SEC
Dec 9, 2025·SEC
Get notified when MRUS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Merus N.V. (MRUS) stock FAQ — growth, dividends, profitability & financials explained
Merus N.V. (MRUS) reported $51.2M in revenue for fiscal year 2024. This represents a 9071% increase from $0.6M in 2013.
Merus N.V. (MRUS) saw revenue decline by 12.4% over the past year.
Merus N.V. (MRUS) reported a net loss of $334.9M for fiscal year 2024.
Merus N.V. (MRUS) has a return on equity (ROE) of -41.4%. Negative ROE indicates the company is unprofitable.
Merus N.V. (MRUS) had negative free cash flow of $317.9M in fiscal year 2024, likely due to heavy capital investments.